134 related articles for article (PubMed ID: 12112387)
21. Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons.
Snyder RD
Drug Chem Toxicol; 2003 Feb; 26(1):15-22. PubMed ID: 12643037
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
Vuong MC; Hasegawa LS; Eastmond DA
Mutat Res; 2013 Jan; 750(1-2):63-71. PubMed ID: 23000430
[TBL] [Abstract][Full Text] [Related]
23. Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.
Gollapudi P; Bhat VS; Eastmond DA
Mutat Res Genet Toxicol Environ Mutagen; 2019 May; 841():49-56. PubMed ID: 31138411
[TBL] [Abstract][Full Text] [Related]
24. Modulation of radiation response by inhibiting topoisomerase II catalytic activity.
Mateos S; Hajji N; Pastor N; Cortés F
Mutat Res; 2006 Jul; 599(1-2):105-15. PubMed ID: 16574164
[TBL] [Abstract][Full Text] [Related]
25. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells.
Snyder RD; Gillies PJ
Environ Mol Mutagen; 2002; 40(4):266-76. PubMed ID: 12489117
[TBL] [Abstract][Full Text] [Related]
28. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
29. Merbarone induces activation of caspase-activated DNase and excision of chromosomal DNA loops from the nuclear matrix.
Otake Y; Mims A; Fernandes DJ
Mol Pharmacol; 2006 Apr; 69(4):1477-85. PubMed ID: 16434617
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
31. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
32. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Francis GE; Tejedor MC; Berney JJ; Chresta CM; Delgado C; Patel P
Leukemia; 1994 Jan; 8(1):121-8. PubMed ID: 8289477
[TBL] [Abstract][Full Text] [Related]
33. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
34. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
35. In vivo genotoxicity of dichloroacetic acid: evaluation with the mouse peripheral blood micronucleus assay and the single cell gel assay.
Fuscoe JC; Afshari AJ; George MH; DeAngelo AB; Tice RR; Salman T; Allen JW
Environ Mol Mutagen; 1996; 27(1):1-9. PubMed ID: 8625942
[TBL] [Abstract][Full Text] [Related]
36. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
Clifford B; Beljin M; Stark GR; Taylor WR
Cancer Res; 2003 Jul; 63(14):4074-81. PubMed ID: 12874009
[TBL] [Abstract][Full Text] [Related]
37. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
39. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
